Alps Advisors Inc. Purchases 6,478 Shares of Albireo Pharma Inc (ALBO)

Share on StockTwits

Alps Advisors Inc. increased its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 30.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,659 shares of the biopharmaceutical company’s stock after acquiring an additional 6,478 shares during the quarter. Alps Advisors Inc.’s holdings in Albireo Pharma were worth $678,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in shares of Albireo Pharma by 315.3% during the 3rd quarter. Wells Fargo & Company MN now owns 4,676 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 3,550 shares during the last quarter. MetLife Investment Advisors LLC boosted its position in shares of Albireo Pharma by 55.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 7,312 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 2,599 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Albireo Pharma by 83.3% during the 3rd quarter. Acadian Asset Management LLC now owns 8,513 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 3,868 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Albireo Pharma by 40.2% during the 4th quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 3,743 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Albireo Pharma during the 2nd quarter valued at about $476,000. 66.61% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ ALBO opened at $26.00 on Thursday. Albireo Pharma Inc has a 12 month low of $19.10 and a 12 month high of $39.35. The stock has a market capitalization of $311.46 million, a price-to-earnings ratio of -8.21 and a beta of 1.74.

Albireo Pharma (NASDAQ:ALBO) last posted its earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.20). The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.55 million. Equities research analysts forecast that Albireo Pharma Inc will post -3.7 EPS for the current fiscal year.

Several research analysts have recently weighed in on ALBO shares. Wedbush reissued a “buy” rating and set a $69.00 price target on shares of Albireo Pharma in a research report on Wednesday, October 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 target price on shares of Albireo Pharma in a research report on Tuesday, November 13th. BidaskClub cut shares of Albireo Pharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 13th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, November 14th. Finally, Zacks Investment Research cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $51.25.

WARNING: This news story was published by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://weekherald.com/2019/02/14/alps-advisors-inc-purchases-6478-shares-of-albireo-pharma-inc-albo.html.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

See Also: Stochastic Momentum Index (SMI)

Want to see what other hedge funds are holding ALBO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albireo Pharma Inc (NASDAQ:ALBO).

Institutional Ownership by Quarter for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply